Artivion, Inc. (NYSE:AORT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Artivion, Inc. (NYSE:AORT) by 58.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 340,887 shares of the company’s stock after purchasing an additional 125,668 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.81% of Artivion worth $9,074,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its stake in Artivion by 3.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock valued at $392,000 after acquiring an additional 481 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Artivion by 3.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after purchasing an additional 600 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Artivion by 6.6% during the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock worth $280,000 after purchasing an additional 653 shares during the last quarter. nVerses Capital LLC acquired a new position in Artivion in the second quarter worth about $28,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in Artivion by 5.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock valued at $713,000 after buying an additional 1,634 shares during the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the sale, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. The trade was a 8.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the completion of the transaction, the vice president now directly owns 33,503 shares of the company’s stock, valued at $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.10% of the company’s stock.

Artivion Price Performance

Shares of AORT opened at $29.66 on Monday. Artivion, Inc. has a 12 month low of $16.48 and a 12 month high of $30.10. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock has a fifty day moving average price of $27.39 and a 200 day moving average price of $26.03. The company has a market cap of $1.24 billion, a P/E ratio of -1,483.00 and a beta of 1.75.

Analyst Ratings Changes

A number of research analysts have commented on AORT shares. JMP Securities initiated coverage on Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price on the stock. Stifel Nicolaus lifted their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and set a $30.00 target price on shares of Artivion in a report on Friday, September 27th. Finally, Oppenheimer raised their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.00.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.